We read with great interest the study by Xiong et al. [1] . Yi Xiong et al. focus on the single nucleotide polymorphism (SNP) of non-small cell lung cancer (NSCLC) and DNA repair pathway based on the view of pharmacogenomics in NSCLC. And they discussed the relationship between the variation of DNA repair genes and the platinum-based chemotherapy in NSCLC treatment.
However, in the Yi Xiong et al.'s study, we found errors which should be checked and corrected. Firstly, Yi Xiong et al. confused the data of first [2] cite with second [3] cite, in the Reck et al.'s study (the first one), the number of deaths from lung cancer representing 19% of all cancer death in 2010 [2] . It is notable that Yi Xiong et al. only used Khuri's data [3] , but cited both of them. And another mistake is the short form of non-small cell lung cancer is NSCLC, not NSCLS.
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